312 related articles for article (PubMed ID: 11699313)
1. [Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors].
Herkel U; Pfeiffer N
Ophthalmologe; 2001 Oct; 98(10):929-33. PubMed ID: 11699313
[TBL] [Abstract][Full Text] [Related]
2. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Michaud JE; Friren B;
Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
[TBL] [Abstract][Full Text] [Related]
3. [Azarga, a new and useful fixed combination in glaucoma treatment].
Călugăru M; Călugăru D
Oftalmologia; 2011; 55(3):38-46. PubMed ID: 22428291
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Silver LH
Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
[TBL] [Abstract][Full Text] [Related]
6. Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma.
Januleviciene I
Curr Med Res Opin; 2010 Nov; 26(11):2575-8. PubMed ID: 20868340
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy on intraocular pressure and retinal blood flow of a beta-blocker (timolol maleate) against the fixed association of a topical carbonic anhydrase (dorzolamide) and a beta-blocker (timolol maleate).
Brogliatti B; Rolle T; Vizzeri GM; Cipullo D
Acta Ophthalmol Scand Suppl; 2000; (232):47-9. PubMed ID: 11235534
[No Abstract] [Full Text] [Related]
8. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
Gugleta K
Curr Med Res Opin; 2010 Jun; 26(6):1255-67. PubMed ID: 20350146
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients.
Martínez A; Sánchez-Salorio M
J Ocul Pharmacol Ther; 2009 Jun; 25(3):239-48. PubMed ID: 19348600
[TBL] [Abstract][Full Text] [Related]
10. Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension.
Croxtall JD; Scott LJ
Drugs Aging; 2009; 26(5):437-46. PubMed ID: 19552495
[TBL] [Abstract][Full Text] [Related]
11. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension.
Heijl A; Strahlman E; Sverrisson T; Brinchman-Hansen O; Puustjärvi T; Tipping R
Ophthalmology; 1997 Jan; 104(1):137-42. PubMed ID: 9022118
[TBL] [Abstract][Full Text] [Related]
12. Fixed topical combinations in glaucomatous patients and ocular discomfort.
Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of a topical carbonic anhydrase inhibitor in patients affected by chronic simple glaucoma.
D'Andrea A; D'Andrea D; Ferreri G
Acta Ophthalmol Scand Suppl; 1998; (227):36-8. PubMed ID: 9972339
[TBL] [Abstract][Full Text] [Related]
14. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
March WF; Ochsner KI
Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
16. [Mode of action, clinical profile and relevance of carbonic anhydrase inhibitors in glaucoma therapy].
Eichhorn M
Klin Monbl Augenheilkd; 2013 Feb; 230(2):146-9. PubMed ID: 23430679
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
García Sanchez J
Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
Sugrue MF
Prog Retin Eye Res; 2000 Jan; 19(1):87-112. PubMed ID: 10614682
[TBL] [Abstract][Full Text] [Related]
19. Switching from dorzolamide to brinzolamide: effect on intraocular pressure and patient comfort.
Inoue K; Wada SA; Wakakura M; Inoue J; Tomita G
Jpn J Ophthalmol; 2006; 50(1):68-9. PubMed ID: 16453193
[No Abstract] [Full Text] [Related]
20. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]